Our CEO, Ángel Alberich-Bayarri, and CMO, Glen Weiss, MD, MBA, attended these days the 38th Annual Meeting & Pre-Conference Programs, #SITC2023. Deeply involved in the scientific, developmental and practical aspects of #cancer immunology and #immunotherapy, this was the perfect opportunity to network with professionals and experts in the field. Through collaborative efforts and seamless integration, we strive to contribute to the transformative progress envisioned
What if we measure the carbon footprint of our #AImodels? Our CEO Ángel Alberich-Bayarri argues in this article for European Hospital that, while the usage of #deeplearning algorithms for positive purposes is increasing, we cannot ignore the carbon footprint created when we train a deep learning model. Also, Ana Jiménez Pastor, VP of AI at Quibim, delves on the social angle of #AI and how the automation of image interpretation could address the global shortage of radiologists, especially in lower-middle-income countries. Read the full article here https://bit.ly/3u1ckYF
Here is the FDA's updated list of AI/ML devices, a critical requirement that we uphold with the utmost seriousness. 📊 Key takeaways: - Distinction in radiology: The field led with 87% of the licensed devices in 2022, advancing to 79% by July 2023, indicating a consistent upward trajectory in submissions. - Expansion across specialties: The collective efforts in cardiovascular, neurology, gastroenterology/urology, anesthesiology, ophthalmology, clinical chemistry, ENT, and hematology paint a diverse and vibrant picture of the AI/ML device landscape. - Evolving complexity: The spectrum of #machinelearning models, ranging from shallow to deep, underscores a shift towards hybrid strategies that blend various algorithms for augmented safety and efficacy. Quibim plays an active role in the AI/ML #healthcare narrative. Our unyielding commitment to fostering a future where cutting-edge tech reshapes healthcare standards shines brighter than ever. 🌟 Find all the info here: https://bit.ly/3FIw1a1
🌸 With the end of October, #BreastCancerAwarenessMonth concludes. We can't stress enough the importance of #EarlyDetection and its important research insights. MRI screening has emerged as an indispensable tool for the early detection of invasive #breastcancer, particularly in high-risk individuals. A meticulous study by Ghuman et al. (from 50 screen-detected breast cancers in 47 women identified between 2016-2022) has shed light on the characteristics and outcomes of MRI-screen-detected breast cancers. 💡 Key Findings: - 64% of the total cancers detected were invasive. Pathology unveiled various types: 36% DCIS, 52% Invasive Ductal Carcinoma (IDC), 10% Invasive Lobular Carcinoma, and 2% Angiosarcoma. - A significant 91% of patients were diagnosed at stage 0 or 1, with no breast cancer-related deaths reported during follow-up periods. 95.7% of patients showed no evidence of disease during an average follow-up of 33 months. - Cancers manifested as masses in 50% of cases, nonmass enhancement in 48%, and a focus in 2%. DCIS predominantly presented as nonmass enhancement (94.4%). 🏥 Clinical Implications: Understanding the predominant imaging features of breast cancers found on screening #MRI enables radiologists to make more accurate diagnoses. Let's spread the word and encourage our network to prioritize regular screenings and stay informed about the advancements in breast cancer research! 🔗 Read the full study here: https://bit.ly/45VD0r5
As #LiverCancerAwareness month comes to an end, we highlight the game-changing impact of deep learning algorithms and #AI on #liver medical imaging. AI is pivotal in medical imaging fields like #radiology, ultrasound, and nuclear medicine. Its diverse applications empower doctors with precise and consistent imaging diagnoses, significantly lightening their workload. 🔎 Harnessing this cutting-edge technology to improve the diagnosis of liver disease, our dedication to leading advances remains unwavering. We're all in for early detection, precise treatment, and enhanced #patientcare. Let's shape a future where liver disease is more comprehensively understood and treated. https://lnkd.in/eRHUVrCd #HealthInnovation #DigitalHealth #PrecisionMedicine
Do you want to collaborate in the development of AI-powered tools for #cancer? The CHAIMELEON Project Open Challenges offer an opportunity for scientists to advance in cancer research with #AI, developing new solutions that have a significant impact on both the development and diagnosis of cancer. Learn more about how this project works clicking in the link https://lnkd.in/dhE_Hqwf. Prostate Challenges are already open! Don't miss this unique opportunity to contribute to the development of AI-powered tools for cancer.
Our CEO Ángel Alberich-Bayarri spoke to The PR Office’s podcast🎙️PROTalks🎙️ about the positive impact of AI and the need to spread the word about the benefits of it when it comes to improving health outcomes across the globe. He was joined by Monica Crespo Chanis, Marc Cohen and Gabriel Hedengren for an insightful and positive chat – have a listen! 🔊
Exciting news! Philips and Quibim team up for the integration of Quibim's pioneering QP-Prostate solution and other future solutions directly into the console of Philips' state-of-the-art #MRI machines. This non-exclusive collaboration, focused on prostate cancer and beyond, will combine Philips’ AI-based MR imaging techniques and Quibim’s AI-enabled image algorithms to: - Help clinicians deliver faster, easier prostate cancer care; - Contribute to mitigate staff shortages; and - Lower the cost of care. Click here to read more bit.ly/3MgzG2L #EarlyDiagnosis #ProstateCancer #PersonalizedTreatments #MRI
As #ESMO2023 closes its doors and we patiently await #ESMO2024, Fuensanta Bellvís Bataller, VP of Clinical Studies, wanted to share some inspiring ideas to wrap up this year's event: "Treating cancer is not one-size-fits-all. Each patient's cancer is unique, making personalized treatment crucial through effectiveness maximization and side effects minimization." 📢 Follow us to stay tuned for more in-depth insights from other quibimers! #ESMO2023 #OncologyInnovations #MedicalAdvances
As proud members of the European Federation for Cancer Images (EUCAIM) project, we are delighted to share an informative video that provides a concise and comprehensive overview of EUCAIM's ambitious goals. At the heart of this transformative effort is QP-Insights®, our orchestration platform that serves as the backbone between clinicians and researchers. QP-Insights® takes the lead in managing, indexing and storing #imagedata, connecting this information with additional clinical variables, and making the most comprehensive results available through the integration and implementation of innovative #AImodels. Do you know about this game-changing European project?
